Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Qingdao Haijingling Seaweed Group is a leading Chinese marine biotechnology company specializing in the research, development, and industrialization of seaweed-derived products. Founded in 2006 and headquartered in Qingdao, the company utilizes advanced extraction technologies such as enzymatic hydrolysis and membrane separation to produce high-value marine biopolymers, including seaweed polysaccharides, fucoidan, and medical-grade alginates. These products are utilized across the healthcare, pharmaceutical, and agricultural industries, with a specific focus on functional health supplements and advanced wound care materials. Haijingling is recognized as a national high-tech enterprise and maintains a strong R&D focus on the therapeutic applications of marine resources for immune modulation and tissue regeneration.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Haijingling.